News Conference News ESC 2024 Asundexian for AF? More Details on the Sinking of OCEANIC-AF Shelley Wood September 02, 2024
News Conference News ESC 2023 FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF Shelley Wood August 28, 2023
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2017 EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib Todd Neale September 05, 2017
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News ESC 2016 NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry Michael O'Riordan August 28, 2016